BioCardia: FDA Says CardiAMP HF II May PMA For Cell Therapy In Ischemic HFrEF; Stock Up

BioCardia said the U.S. FDA has confirmed its pivotal Phase 3 CardiAMP Heart Failure II trial may support a Premarket Approval application for CardiAMP Cell Therapy in ischemic heart failure. The decision materially improves the regulatory path for the therapy and reduces a key development risk. The update is supportive for BCDA shares, though the article does not include efficacy data or a final approval decision.

Analysis

BioCardia said the U.S. FDA has confirmed its pivotal Phase 3 CardiAMP Heart Failure II trial may support a Premarket Approval application for CardiAMP Cell Therapy in ischemic heart failure. The decision materially improves the regulatory path for the therapy and reduces a key development risk. The update is supportive for BCDA shares, though the article does not include efficacy data or a final approval decision.